Last reviewed · How we verify
targeted synthetic DMARD class
This targeted synthetic DMARD class drug works by selectively inhibiting a specific molecular target to modulate the immune response.
This targeted synthetic DMARD class drug works by selectively inhibiting a specific molecular target to modulate the immune response. Used for Rheumatoid arthritis.
At a glance
| Generic name | targeted synthetic DMARD class |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Targeted synthetic DMARD |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The drug's mechanism of action involves the selective inhibition of a specific molecular target, which leads to a reduction in inflammation and an improvement in symptoms associated with autoimmune diseases. This targeted approach allows for a more precise modulation of the immune response, reducing the risk of adverse effects associated with broader immunosuppressive therapies.
Approved indications
- Rheumatoid arthritis
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- RA-PRO PRAGMATIC TRIAL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- targeted synthetic DMARD class CI brief — competitive landscape report
- targeted synthetic DMARD class updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI